Skip to main content
Bascom Palmer
  • Calendar
  • SPECIALTIES
    Cataracts and Intraocular Lenses Comprehensive Ophthalmology Corneal and External Diseases Glaucoma Neuro-Ophthalmology Ocular Oncology Ophthalmic Pathology Ophthalmic Plastic and Reconstructive Surgery Pediatric Ophthalmology and Strabismus Retina and Vitreous Diseases Uveitis
  • FILTER BY
    Online Grand Rounds Medical Student Education Ophthalmic Images Other Lectures Surgical Videos
  • SEARCH
  • More
Site-wide search Close
Toggle search input
guest access
Log in
Bascom Palmer
Calendar SPECIALTIES Collapse Expand
Cataracts and Intraocular Lenses Comprehensive Ophthalmology Corneal and External Diseases Glaucoma Neuro-Ophthalmology Ocular Oncology Ophthalmic Pathology Ophthalmic Plastic and Reconstructive Surgery Pediatric Ophthalmology and Strabismus Retina and Vitreous Diseases Uveitis
FILTER BY Collapse Expand
Online Grand Rounds Medical Student Education Ophthalmic Images Other Lectures Surgical Videos
SEARCH
Expand all Collapse all
  1. Dashboard
  2. Angio020324
  3. Description
  4. THE DAVIO 2 TRIAL: Topline Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration by Charles C. Wykoff, MD, PhD

THE DAVIO 2 TRIAL: Topline Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration by Charles C. Wykoff, MD, PhD

Completion requirements
Click on THE DAVIO 2 TRIAL: Topline Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration by Charles C. Wykoff, MD, PhD to open the resource.
◄ First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD by Arshad M. Khanani, MD, MA
96-week Efficacy and Safety of Aflibercept 8 mg in nAMD: An Update from the PULSAR Study by W. Lloyd Clark, MD ►
guest access (Log in)
Data retention summary
Powered by Moodle
 
  • Medical Disclaimer
  • |
  • Terms of Use
  • |
  • Privacy Statement
  • |
  • HIPAA Notice of Privacy Practices
  • |
  • About Us
  • |
  • FAQs

© 2026 University of Miami Health Systems. All Rights Reserved.